Hydrocortisone plus fludrocortisone for adults with septic shock.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Septic shock is characterized by dysregulation of the host response to infection, with circulatory, cellular, and metabolic abnormalities. We hypothesized that therapy with hydrocortisone plus fludrocortisone or with drotrecogin alfa (activated), which can modulate the host response, would improve the clinical outcomes of patients with septic shock. METHODS: In this multicenter, double-blind, randomized trial with a 2-by-2 factorial design, we evaluated the effect of hydrocortisone-plus-fludrocortisone therapy, drotrecogin alfa (activated), the combination of the three drugs, or their respective placebos. The primary outcome was 90-day all-cause mortality. Secondary outcomes included mortality at intensive care unit (ICU) discharge and hospital discharge and at day 28 and day 180 and the number of days alive and free of vasopressors, mechanical ventilation, or organ failure. After drotrecogin alfa (activated) was withdrawn from the market, the trial continued with a two-group parallel design. The analysis compared patients who received hydrocortisone plus fludrocortisone with those who did not (placebo group). RESULTS: Among the 1241 patients included in the trial, the 90-day mortality was 43.0% (264 of 614 patients) in the hydrocortisone-plus-fludrocortisone group and 49.1% (308 of 627 patients) in the placebo group (P=0.03). The relative risk of death in the hydrocortisone-plus-fludrocortisone group was 0.88 (95% confidence interval, 0.78 to 0.99). Mortality was significantly lower in the hydrocortisone-plus-fludrocortisone group than in the placebo group at ICU discharge (35.4% vs. 41.0%, P=0.04), hospital discharge (39.0% vs. 45.3%, P=0.02), and day 180 (46.6% vs. 52.5%, P=0.04) but not at day 28 (33.7% and 38.9%, respectively; P=0.06). The number of vasopressor-free days to day 28 was significantly higher in the hydrocortisone-plus-fludrocortisone group than in the placebo group (17 vs. 15 days, P<0.001), as was the number of organ-failure-free days (14 vs. 12 days, P=0.003). The number of ventilator-free days was similar in the two groups (11 days in the hydrocortisone-plus-fludrocortisone group and 10 in the placebo group, P=0.07). The rate of serious adverse events did not differ significantly between the two groups, but hyperglycemia was more common in hydrocortisone-plus-fludrocortisone group. CONCLUSIONS: In this trial involving patients with septic shock, 90-day all-cause mortality was lower among those who received hydrocortisone plus fludrocortisone than among those who received placebo. (Funded by Programme Hospitalier de Recherche Clinique 2007 of the French Ministry of Social Affairs and Health; APROCCHSS ClinicalTrials.gov number, NCT00625209 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the ADRENAL [479] study, hydrocortisone was administered for a maximum of seven days or until ICU discharge or death; in APROCCHSS [478] hydrocortisone was administered for seven days; in VANISH [354] 200 mg of hydrocortisone was administered daily for 5 days and then tapered over further 6 days.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“In APROCCHSS [478] the dose of vasopressor was ≥ 0.25 µg/kg/min or ≥ 1 mg/h of norepinephrine or epinephrine, or any other vasopressor for at least 6 h to maintain a MAP ≥ 65 mmHg.”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
In the citing paper
“Since then, three large RCTs have been published [354, 478, 479].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [478]
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Self-citationDellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Self-citationVincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Annane, D. (2002) · JAMA · doi:10.1001/jama.288.7.862 · Cited by 3,087
Self-citationShankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., Angus, D. C., Rubenfeld, G. D., Singer, M., & for the Sepsis Definitions Task Force (2016) · JAMA · doi:10.1001/jama.2016.0289 · Cited by 2,424
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Self-citationAnnane, D., Bellissant, E., & Cavaillon, J.-M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17667-8 · Cited by 1,213
Self-citationAnnane, D., Vignon, P., Renault, A., Bollaert, P.-E., Charpentier, C., Martin, C., Troché, G., Ricard, J.-D., Nitenberg, G., Papazian, L., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61344-0 · Cited by 567
Self-citationCognitive decline after sepsis.
Annane, D., & Sharshar, T. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70246-2 · Cited by 290
Self-citation
Research works printed but not linked: 1
- Guide “100 recommandations pour la surveillance et la préventions des infections nosocomiales.” Bulletin Epidémiologique Hebdomadaire. No. 48. November 30 1992 (http://invs.santepubliquefrance.fr/beh/1992/48/index.html).
Cited by
Items 801–900 of 968
Die aktuelle Sepsisleitlinie – was müssen Sie wissen?
Kochanek, M., & David, S. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01585-z
Çalılı, D. K., İzdeş, Ş., & Öztürk, L. (2023) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/jcmk/13690
Vaught, A. “. J. (2023) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-023-00370-x
“Two different trials used different inclusion for the use of hydrocortisone in septic shock: • ADRENAL were started on hydrocortisone when a MAP ≥ 60 mmHg was not achieved for greater than 4 h [15].”
Hot and shocky: Distributive/septic shock
Aydin, A., & Mathews, K. S. (2023) · Oxford University Press eBooks · doi:10.1093/med/9780190082581.003.0012
Marino, L. O., Gómez, L. M. G., Barbeiro, D. F., Barbeiro, H. V., Brandao, R. A., Menezes, M. C. S., Bachegda, T. A. S. S., & de Sousa, H. P. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4667597
Journal of Shock and Hemodynamics, Vol. I, Iss. 2 (print version)
(2023) · Journal of shock & hemodynamics · doi:10.58464/2836-0605.1039
Torchio, M., & Ceccato, F. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01422-x
Zhong, J. J., Zhang, J., Lin, Y. Y., Ju, D., Mo, J., & Ye, X.-Z. (2024) · Preprints.org · doi:10.20944/preprints202402.0264.v1
Montero, V. R., Ribes, C. M., Montell, M. P., & Zaragoza, R. (2022) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2022.03.008
Estrategia integral de reanimación del paciente con sepsis y shock séptico
del Río-Carbajo, L., Olmo, J. N.-D., Fernández‐Ugidos, P., & Vidal, P. (2022) · Medicina Intensiva (English Edition) · doi:10.1016/j.medine.2022.02.025
Dysfonction myocardique du sepsis : de la physiopathologie au traitement
Razazi, K. (2022) · theses.fr (ABES) · doi:10.70675/7cb91164z6fd8z434az8fb9z1f44d83f99b8
Jindal, A., & Angadi, V. M. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24636
“5 To negate such confounding effects, a pragmatic study design would be one using matched controls or providing comparative analysis using inferential statistics.”
BackgroundKochanek, M., & David, S. (2024) · Wiener klinisches Magazin · doi:10.1007/s00740-024-00527-1
Early intravenous hydrocortisone in sepsis: A randomized control trial (Protocol)
Pansiritanachot, W., Permpikul, C., Tongyoo, S., Chakorn, T., Wongprompitak, P., & Senawong, S. (2024) · Clinical Critical Care · doi:10.54205/ccc.v32.267616
Progress in the Diagnosis and Treatment of Pediatric Septic Shock
洪, 婧. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441211
Tamura, T., & Sasaki, J. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.857
Kapadia, F. N., Sharma, R., & Bharadwaj, S. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24717
Tandon, M. S., Sharma, A., Mittal, R., & Bhandari, N. (2024) · Springer eBooks · doi:10.1007/978-981-99-8059-8_24
In septic shock and CAP, hydrocortisone + fludrocortisone reduced 90-d mortality
Maki, D. G. (2024) · Annals of Internal Medicine · doi:10.7326/annals-24-00210-jc
Predictive modeling of corticosteroids sensitivity in sepsis using a supervised learning approach
Lannelongue, E., Grimaud, A., Tillier, C., & Annane, D. (2025) · Journal of Applied Statistics · doi:10.1080/02664763.2025.2593309
Self-citationConducta práctica ante un estado de shock séptico
Levy, M., Naudin, J., Caséris, M., Geroteo, J. S., & Dauger, S. (2024) · EMC - Pediatría · doi:10.1016/s1245-1789(24)49327-x
Glucocorticoids and sepsis and 28-day mortality of sepsis: a Mendelian randomization studyPreprint
Huang, J., Xie, Y., & Huang, H. (2024) · Research Square · doi:10.21203/rs.3.rs-4805652/v1
Hydrocortisone for Septic Shock, Bolus or Infusion: Pro, Con, May be
Todi, S. K. (2024) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24798
“8,9 In this issue of the journal, a randomized study has been conducted in 40 patients with septic shock requiring a vasopressor comparing a hydrocortisone bolus of 50 mg 6 hours a day with a continuous infusion of hydrocortisone of 200 mg over 24 hours.”
BackgroundTeja, B. J. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202407-1437le
True Effect of Fludrocortisone for Septic Shock: Baseline Risk and Transitivity Concerns
Yoshihiro, S., & Taito, S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1104le
Changes in carotid corrected flow time in guiding fluid resuscitation in septic patients
Sabri, S., Abdelbasset, A., Yassien, A., & Nashaat, A. (2022) · Research and Opinion in Anesthesia and Intensive Care · doi:10.4103/roaic.roaic_60_21
SASA Refresher Course Abstracts
Editorial Office (2024) · Southern African Journal of Anaesthesia and Analgesia · doi:10.36303/sajaa.3214
Coudereau, R. (2023) · theses.fr (ABES) · doi:10.70675/d8dd405fz1435z4d72z9191z26e62d4202f9
Hydroxocobalamin for the treatment of vasoplegia after lung transplantation: A case series
Nguyễn, A. T., Bouajram, R. H., Brzeziński, M., Hassanipour, S., Gordon, D., Trinh, B., Deuse, T., Venado, A. E., Hays, S. R., Singer, J. P., et al. (2024) · JHLT Open · doi:10.1016/j.jhlto.2024.100189
(2019) · ASA Monitor · doi:10.1097/01.asm.0001078484.95276.34
1565: SHOCKINGLY VAGUE: COMPARING ADJUNCTIVE MEASURES IN SEPTIC SHOCK
Wang, H. F., Cheriyan, B., Huebner, M., Wang, S., & Sudekum, D. (2025) · Critical Care Medicine · doi:10.1097/01.ccm.0001104924.19139.7c
Andrade, G. M. A., da Silveira, S. C., Chaves, L. F. M., & Barros, G. B. D. G. M. (2025) · Revista Foco · doi:10.54751/revistafoco.v18n4-121
Wu, W., Zhang, Y., Zhang, Y.-L., Qu, X., Zhang, Z., Zhang, R., & Peng, Z. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i20.105269
“AP severity was assessed using BISAP score[23,24] and SOFA score[25].”
A double-edged sword: a narrative review on steroids in sepsis and septic shock
Guarino, M., Luppi, F., Perna, B., Maritati, M., Contini, C., Spampinato, M. D., & GIORGIO, R. D. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04008-z
“However, the APROCCHSS trial found no clear benefit of extending treatment beyond the initial shock phase, suggesting that a shorter duration may be sufficient to achieve the desired effects without incurring the risks of prolonged steroid therapy [31].”
Sepsis et choc septique de l’adulte
de Roquetaillade, C., Bousta, A., Muchardt, J., & Chousterman, B. G. (2025) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(25)47121-7
Rochwerg, B. N., Heels‐Ansdell, D., Austin, P., Millen, T., Buckingham, L., D’Aragon, F., Hand, L. E., Guyatt, G. H., Jaeschke, R., Lamontagne, F., et al. (2025) · CHEST Critical Care · doi:10.1016/j.chstcc.2025.100184
Bauer, P. R. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197628638.003.0060
Corticosteroids in septic shock: a double-edged sword
Wang, J. Y., & Kollef, M. H. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001297 · Cited by 1
Danos, A., Lear, A., Roach, E. M., & Quinn, N. J. (2025) · Annals of Pharmacotherapy · doi:10.1177/10600280251355619
“8,9 In addition to this, a hydrocortisone taper was utilized after the 200 mg per day in 41% of patients.”
InfluentialEvaluation of Stress Dose Hydrocortisone Tapers in Septic Shock
Gilchrist, H. E., Roginski, M. A., & Esteves, A. M. (2025) · Hospital Pharmacy · doi:10.1177/00185787251355438
Emami, E., Molaei, E., Ghazi, S. F., Sohrabi, M., & Khalili, H. (2025) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-025-00571-0
“In the APROCCHSS trial [ 10 ], it was used for a fixed 7-day course and in the VANISH trial [23], HC was applied for 5 days, followed by a 6-day taper.”
Indications for corticosteroids in the treatment of Community-Acquired pneumonia
Blot, M., Basille, D., Dinh, A., Barbier, F., & Fillâtre, P. (2025) · Infectious Diseases Now · doi:10.1016/j.idnow.2025.105127
Zhang, Z., Bai, Y., Yang, Z., & Ren, S. (2025) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2025.07.203
Jeon, C. H., Sung, K., & Cho, J. (2025) · Surgical Infections · doi:10.1177/10962964251376959
Hydrocortisone in Septic Shock: The ADRENAL Trial
Chacko, J., Chalfin, D. B., Seppelt, I., Pawar, S., & Brar, G. (2025) · Springer eBooks · doi:10.1007/978-981-95-0673-6_31
Araneda, R. M., Moreno, V. M., Bustillos, A. C., & Peralta, F. V. (2025) · Revista Chilena de Anestesia · doi:10.25237/revchilanestv54n5-02
Sepsis y shock séptico en adultos
de Roquetaillade, C., Bousta, A., Muchardt, J., & Chousterman, B. G. (2025) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(25)51018-6
Sepsi e shock settico dell'adulto
de Roquetaillade, C., Bousta, A., Muchardt, J., & Chousterman, B. G. (2025) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(25)51071-x
INTENSIVE CARE MANAGEMENT IN THE ACUTE PHASE OF PNEUMONIA COMPLICATED BY SEPSIS
Kolmakov, A. I., Stepanov, A. Y., Аleksаndrovich, Y. S., Владимировна, Э. Е., & Викторович, П. В. (2025) · Zabajkalʹskij medicinskij vestnik · doi:10.52485/19986173_2025_3_143
Immunonutrition and Pharmaconutrition
Hill, A., & Stoppe, C. (2025) · Springer eBooks · doi:10.1007/978-3-032-00818-3_8
When and How Much? Steroids in Sepsis
CROSLEY, E. L., Yang, P., & Esper, A. M. (2025) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.10.004
Adrenal Insufficiency: Diagnostic Approaches, Treatments, and Outcomes Volume II
(2025) · Frontiers research topics · doi:10.3389/978-2-8325-7003-6
Adrenocortical insufficiency in critical illness
Cohen, J., & Venkatesh, B. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11611-7.00071-2
Moskowitz, A., Andersen, L. W., Holmberg, M. J. J., Grossestreuer, A. V., Berg, K. M., & Granfeldt, A. (2020) · Figshare · doi:10.6084/m9.figshare.12629647
Vaidie, J., Péju, E., Jandeaux, L.-M., Lesouhaitier, M., Lacherade, J.-C., Guillon, A., Wittebole, X., Asfar, P., Evrard, B., Daix, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24078423
Self-citationJung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870328
Additional file 1 of Towards personalized medicine: a scoping review of immunotherapy in sepsis
Slim, M. A., van Mourik, N., Bakkerus, L., Fuller, K., Acharya, L. S., Giannidis, T., Dionne, J. C., Oczkowski, S. J. W., Netea, M. G., Pickkers, P., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26726717
Etablierung und Charakterisierung eines marinen Cecal Slurry Sepsis-Modells
Schäfer, L. S. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033178
Jung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870331
Bagate, F., Bedet, A., Tomberli, F., Boissier, F., Razazi, K., de Prost, N., Carteaux, G., & Dessap, A. M. (2021) · Figshare · doi:10.6084/m9.figshare.14489866
Jung, S.-Y., Lee, M.-T., Baek, M. S., & Kim, W.-Y. (2022) · Figshare · doi:10.6084/m9.figshare.17870334
Liang, B., Su, J., Shao, H., Chen, H., & Xie, B. (2024) · Figshare · doi:10.6084/m9.figshare.26574941
A disfunção endotelial no doente crítico
Malheiro, L. F. G. (2022) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/0tsv-9204
Alamri, S. A. M., Alenazi, A. F. A., Altamimi, E. A. E., Alshammri, N. F. A., Aljuhani, H. F. M., Assiri, S. A. M., Alruwaili, A. R. A., Alreshidi, F. E. B., Ghabban, M. M. R., & Alsharif, E. I. M. (2024) · International Journal of Computational and Experimental Science and Engineering · doi:10.22399/ijcesen.3953
Lee, J. P. (2025) · Springer eBooks · doi:10.1007/978-3-032-07080-7_12
Semer, T. (2025) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Adjunctive Therapies in Sepsis: Corticosteroids, IVIG, Blood Purification, and More
Ekici, H., & Türe, Z. (2025) · doi:10.59537/saupress.2500
Precision Medicine in Sepsis: From Biomarkers to Bedside
MEŞE, E. A., YÜCE, Z. T., Eren, E. E., Tufan, Z. K., Eser, F., Oktay, Z., Beder, D., Yaman, M., Altındiş, M., Baddal, B., et al. (2025) · doi:10.59537/saupress.2486
Case 1-2026: A 50-Year-Old Woman with Fever and Abdominal Pain
Threlkeld, S. C., Anderson, M., Dudzinski, D. M., Anahtar, M. N., Alba, G. A., Basgoz, N. O., Fowler, A. G., & Stone, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmcpc2513324
Sepsis in Cirrhosis: Challenges, Timely Diagnosis, and Optimal Antibiotic Strategies
Singh, S. P., Rudra, O. S., & Jothimani, D. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_16
Huang, Z., Zhao, J., Yuan, Q., Yang, X., & Li, X. (2026) · Research Square · doi:10.21203/rs.3.rs-8297386/v1
Sun, A., Gao, X., Gao, Z., Zhang, Q., & He, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1755626
“A large clinical study (15) comparing the effects of 200 mg of hydrocortisone and fludrocortisone per day versus placebo in patients with severe septic shock showed a decrease in 90-day mortality in the steroid group, as well as earlier reversal of shock and relief from mechanical ventilation.”
Lactate Cut-offs for 28-day Mortality in Septic ShockPreprint
Wanka, S.-T., Hermann, A., Lenz, M., Hengstenberg, C., Schellongowski, P., Staudinger, T., & Zilberszac, R. (2026) · medRxiv · doi:10.64898/2026.02.08.26345840
Khan, A. S., Ahmad, F., Khan, A. A., Khan, Z., Ahmed, T., Wazir, A., Khan, H. U., Ali, A., Khan, H., Khan, A. Y., et al. (2026) · Medical Principles and Practice · doi:10.1159/000551004
“Two landmark clinical trials, ADRENAL and APROCCHSS, yielded conflicting data regarding the impact of hydrocortisone on 90-day survival rates; nevertheless, both studies confirmed that steroids accelerate the resolution of shock and decrease the time patients require mechanical ventilation [9, 10].”
Forte, T. M. (2020) · e_Buah · Cited by 1
Lee, J. H., Sumer‐Bayraktar, Z., Rushworth, R. L., Chernykh, A., Nenke, M. A., Thaysen‐Andersen, M., Meyer, E. J., & Torpy, D. J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag058
“…(HC) use nor serum cortisol was associated with mortality [6], consistent with randomized clinical trials of intravenous glucocorticoid administration, which have shown only marginal mortality benefit [2, 3, 7-10] despite cortisol’s known immunomodulatory and pressor effects [11, 12].”
Corticosteroids for treating sepsis: A systematic review and network meta-analysis
Luo, X., Yang, J., Zhang, Z., Sun, H., Gao, M., & Wu, S. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.108786
Best practices for critically ill patients boarding in the emergency department: A Delphi study
Garcia, S. I., Finch, A. S., Smith, L. M., Mullan, A. F., & Litell, J. M. (2026) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2026.03.028
Mahajan, A., Beattie, N., Patel, N. P., Tran, A. H., Ho, V. P., & Dvorak, J. E. (2026) · Surgical Infections · doi:10.1177/10962964261437315
Kaynar, A. M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1600039
Qui est l'assassin au cours du sepsis? : l'inflammation ou la prolifération bactérienne ?
de Tymowski, C. (2020) · theses.fr (ABES) · doi:10.70675/ed19121fza61fz403czb053z70b4c1f5a3a6
Impact de la corticothérapie dans les infections invasives à Neisseria meningitidis
Levy, M. (2018) · theses.fr (ABES) · doi:10.70675/4267c369z9f77z4ed0z958cze23c84578c13
Rôle du TNFR2 exprimé par les lymphocytes T régulateurs au cours de l'immunodépression post septique
Gaborit, B. (2019) · theses.fr (ABES) · doi:10.70675/fc216760z171az42f4zade0z7695e77ea077
Propriétés immunes de la cellule endothéliale au cours du sepsis
Pons, S. (2021) · theses.fr (ABES) · doi:10.70675/3999fc10z25d2z4513z87dazc18894ab82dd
Stéroïdomique corticosurrénalienne par LC-MS/MS : applications en endocrinologie pédiatrique
Travers, S. A. A. (2020) · theses.fr (ABES) · doi:10.70675/84cf9c3bze93ez41dcza251z559f27f3c6a6
Schémas bayésiens d'enrichissement pour l'intégration de biomarqueurs multiples
Vinnat, V. (2023) · theses.fr (ABES) · doi:10.70675/fe7b0ca3zd9f5z462ezb2eaz6cfcfe072e0f
Immunomodulatory nanoparticles for the treatment of the inflammatory response during sepsis
Louaguenouni, Y. (2024) · theses.fr (ABES) · doi:10.70675/10de0500zcb45z4507z8ad9z3ba9e02f6822
Vermeersch, V. (2023) · theses.fr (ABES) · doi:10.70675/208ba22bz2ec2z47d3z9889z4157016e475d
Implication de l'axe C5a-C5aR1 dans l'orage inflammatoire des formes sévères de COVID-19 de l'adulte
Carvelli, J. (2023) · theses.fr (ABES) · doi:10.70675/be12640bzc919z4322zb146z5a584bd7ec67
Li, Y., Ding, H., & Li, X. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13418-z
Adrenal Emergencies in Critically Ill Cancer Patients
Popovich, J. J., & Enfield, K. B. (2026) · Springer eBooks · doi:10.1007/978-3-319-74698-2_81-2
Pioneers & Pathfinders: 10 Years of Frontiers in Medicine
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7221-4
Fludrocortisone Deserves More Attention in Septic Shock
Rahhal, A. A. A., Sivadasan, P. C., Omar, A. S., & Wieruszewski, P. M. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.05.020
Refractory Shock in the Post–Cardiac Arrest Patient
Walker, A. C., & Johnson, N. J. (2026) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2026.04.003
Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock
Gastanadui, M. G., Murphy, H. R., Shahu, A., Safiriyu, I., Heck, C., Hysolli, M., Callegari, S., Garimella, S., Ali, T. M., Jentzer, J. C., et al. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261437767
Hao, Z., Luan, X., Mi, X., Zhang, C., Ji, N., Wang, Y., Hu, H., Chen, J., Du, Y., Pei, X., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119029
Munroe, E. S., Peltan, I. D., & Prescott, H. C. (2026) · Critical Care Clinics · doi:10.1016/j.ccc.2026.05.002
Metadata
- Authors
- Annane, D., Renault, A., Brun-Buisson, C., Megarbane, B., Quenot, J.-P., Siami, S., Cariou, A., Forceville, X., Schwebel, C., Martin, C., Timsit, J.-F., Misset, B., Ali Benali, M., Colin, G., Souweine, B., Asehnoune, K., Mercier, E., Chimot, L., Charpentier, C., François, B., Boulain, T., Petitpas, F., Constantin, J.-M., Dhonneur, G., Baudin, F., Combes, A., Bohé, J., Loriferne, J.-F., Amathieu, R., Cook, F., Slama, M., Leroy, O., Capellier, G., Dargent, A., Hissem, T., Maxime, V., & Bellissant, E.
- Affiliations
- Inserm (FR)
- From Service de Médecine Intensive et Réanimation, Hôpital Raymond Poincaré, Garches (D.A., V.M.), Laboratory of Infection and Inflammation Unité 1173, University of Versailles Saint-Quentin-en-Yvelines, INSERM, Montigny-le-Bretonneux (D.A.), Service de Pharmacologie Clinique–Centre d’Investigation Clinique (CIC) INSERM 1414, Centre Hospitalier Universitaire (CHU) de Rennes–Université de Rennes 1, Hôpital Pontchaillou, Rennes (A.R., E.B.), Service de Réanimation Médicale (C.B.-B.) and Service...
- ORCID
- Annane, Djillali
- Renault, Alain
- Quenot, Jean-Pierre
- Siami, Shidasp
- Cariou, Alain
- Forceville, Xavier
- Schwebel, Carole
- Misset, Benoît
- Souweine, Bertrand
- Asehnoune, Karim
- François, Bruno
- Boulain, Thierry
- Constantin, Jean-Michel
- Combes, Alain
- Bohé, Julien
- Amathieu, Roland
- Cook, Fabrice
- Slama, Michel
- Capellier, Gilles
- Dargent, Auguste
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-03
- Volume
- 378
- Issue
- 9
- Pages
- 809-818
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2794125559
- Cited by
- 939
- References
- 22
- Citations by year
- 2026: 107 · 2025: 104 · 2024: 97 · 2023: 115 · 2022: 101 · 2021: 98 · 2020: 121 · 2019: 123 · 2018: 70
- FWCI
- 80.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Funders
- Ministère des Affaires Sociales et de la Santé (Programme Hospitalier de Recherche Clinique / P 07)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- cortisol, fludrocortisone, drotrecogin alfa (activated), corticosteroid therapy, host response to infection, 90-day mortality, vasopressor-free days, organ failure, mechanical ventilation, intensive care unit discharge, sepsis treatment
- MeSH terms
- Simplified Acute Physiology Score, Aged, Anti-Inflammatory Agents, Cause of Death, Combined Modality Therapy, Double-Blind Method, Drug Therapy, Combination, Female, Fludrocortisone, Humans, Hydrocortisone, Male, Middle Aged, Recurrence, Respiration, Artificial, Shock, Septic, Survival Analysis, Treatment Outcome, Renal Replacement Therapy, Organ Dysfunction Scores
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.